Our Technology Platform

 

 

Our antibody discovery uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity.


Our technology captures and preserves entire B cell repertoires from any donor species and any B cell type in recombinant form and displays them in mammalian cells, maintaining the cognate heavy and light chain pairing of the original B cells throughout the process.


Our antibody repertoires are screened in single-cell format using our microfluidic screening platforms which can assess millions of candidate antibodies directly in functional assays. The result of the process are recombinant clonal cell lines expressing mAbs with the desired functional properties.

antibody discovery in humans

The human as source of therapeutic antibody candidates offers the unique opportunity to increase the chance for clinical success of a candidate antibody by selecting donors that present with favorable clinical outcomes.

antibody discovery in rabbits

The platform is an outstanding tool to tap into the wealth of the antibody repertoires of any species. As a first animal host we selected the rabbit due to its ability to generate antibodies against human proteins with higher affinity and greater diversity compared to other rodents. Applying MemoMAB with immunized rabbits we expect to identify 10-100x more antibodies compared to conventional technologies with an unmatched epitope coverage and high affinities. Our high-content-interrogation of the repertoire libraries using our microfluidic screening technologies delivers portfolios of antibodies with the desired features in weeks. The full compatibility of the MemoMAB system for subsequent functional and animal studies speeds up discovery and development timelines considerably.